Printer Friendly

US FDA Grants Orphan Drug Designation to Enzychem Lifesciences Treatment for Acute Radiation Syndrome.

M2 PHARMA-January 26, 2018-US FDA Grants Orphan Drug Designation to Enzychem Lifesciences Treatment for Acute Radiation Syndrome

(C)2018 M2 COMMUNICATIONS

- Seoul, South Korea-based biopharmaceutical company Enzychem Lifesciences, Corp. (KONEX: 183490) has been granted Orphan Drug Designation by the US Food and Drug Administration for EC-18 for the treatment of acute radiation syndrome, the company said.

Caused by a critical exposure to radiation, acute radiation syndrome includes neutropenia, nervous system damage, and pneumonia with high fatality rate.

EC-18 is a small molecule compound designed for oral administration that could have a role in treating immune and inflammatory related diseases, including psoriasis, rheumatoid arthritis, asthma, atopic dermatitis, and sepsis.

Enzychem Lifesciences is conducting phase II clinical trials on indications of chemotherapy-induced neutropenia and chemo-radiotherapy induced oral mucositis in the United States.

Enzychem Lifesciences is a global new drug development company with an R and D driven approach. The company is developing innovative treatments which can address significant unmet medical needs.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2018 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Jan 26, 2018
Words:170
Previous Article:Alligator Bioscience names Theradex Oncology as clinical CRO for the upcoming ATOR-1015 phase I study.
Next Article:UPM Pharmaceuticals Promotes Curtin to COO.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters